利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.019 秒)

    Diagnosis of infection in the lungs of patients
    1.
    再颁专利
    Diagnosis of infection in the lungs of patients 有权
    诊断患者肺部感染

    公开(公告)号：USRE44533E1

    公开(公告)日：2013-10-08

    申请号：US13467514

    申请日：2012-05-09

    申请人： Graham Timmins ,  Vojo P. Deretic

    发明人： Graham Timmins ,  Vojo P. Deretic

    IPC分类号： A61B5/08

    CPC分类号： C12Q1/04 ,  A61K51/04 ,  A61K51/0406 ,  A61K51/1206 ,  G01N33/497 ,  G01N2333/21

    摘要： The present invention relates to methods for detecting P aeruginosa infection and bacterial burden in the lungs of patients who are at risk for P. aeruginosa infections, especially including patients with Cystic Fibrosis (CF). The present method provides numerous tests (breath, blood, urine) which are readily administered to a patient that will sensitively and specifically detect the presence and extent of lung infection P. aeruginosa (both mucoid and non-mucoid), and allow monitoring of bacterial load as a parameter in monitoring treatment.

    摘要翻译： 本发明涉及用于检测铜绿假单胞菌感染风险的患者肺部铜绿假单胞菌感染和细菌负担的方法，特别是包括囊性纤维化（CF）患者。 本方法提供了许多试验（呼吸，血液，尿液），其易于对患者施用，其将敏感且特异性地检测肺部感染铜绿假单胞菌（粘液样和非粘液样）的存在和程度，并允许监测细菌 负载作为监测治疗的参数。

    Diagnosis of P. aeruginosa infection in the lungs of patients
    2.
    发明授权
    Diagnosis of P. aeruginosa infection in the lungs of patients 有权
    诊断患者肺部铜绿假单胞菌感染

    公开(公告)号：US07717857B2

    公开(公告)日：2010-05-18

    申请号：US12150199

    申请日：2008-04-25

    申请人： Graham Timmins ,  Vojo P. Deretic

    发明人： Graham Timmins ,  Vojo P. Deretic

    IPC分类号： A61B5/08

    CPC分类号： C12Q1/04 ,  A61K51/04 ,  A61K51/0406 ,  A61K51/1206 ,  G01N33/497 ,  G01N2333/21

    摘要： The present invention relates to methods for detecting P aeruginosa infection and bacterial burden in the lungs of patients who are at risk for P. aeruginosa infections, especially including patients with Cystic Fibrosis (CF). The present method provides numerous tests (breath, blood, urine) which are readily administered to a patient that will sensitively and specifically detect the presence and extent of lung infection P. aeruginosa (both mucoid and non-mucoid), and allow monitoring of bacterial load as a parameter in monitoring treatment.

    摘要翻译： 本发明涉及用于检测铜绿假单胞菌感染风险的患者肺部铜绿假单胞菌感染和细菌负担的方法，特别是包括囊性纤维化（CF）患者。 本方法提供了许多试验（呼吸，血液，尿液），其易于对患者施用，其将敏感且特异性地检测肺部感染铜绿假单胞菌（粘液样和非粘液样）的存在和程度，并允许监测细菌 负载作为监测治疗的参数。

    Non-invasive rapid diagnostic test for M. tuberculosis infection
    5.
    发明授权
    Non-invasive rapid diagnostic test for M. tuberculosis infection 有权
    结核分枝杆菌感染的非侵入性快速诊断试验

    公开(公告)号：US07897400B2

    公开(公告)日：2011-03-01

    申请号：US11955773

    申请日：2007-12-13

    申请人： Graham Timmins ,  Vojo P. Deretic

    发明人： Graham Timmins ,  Vojo P. Deretic

    IPC分类号： G01N33/00 ,  A61K31/44

    CPC分类号： A61B5/0002 ,  A61B5/082 ,  A61B5/411 ,  A61B5/415 ,  A61B5/416 ,  A61B5/418 ,  A61K49/0004 ,  G01N33/5695

    摘要： This invention relates to a test for detecting a Mycobacterium tuberculosis (tuberculosis or TB) infection in a patient or subject, specifically a diagnostic test, including a breath test, whereby patients are provided a small dose of an isotopically labeled TB drug, Isoniazid (INH) orally or directly to the lungs of the patient or subject. If TB is present, a TB enzyme mycobacterial peroxidase KatG oxidizes the INH; and KatG specific metabolites, in particular, isotopically labeled nitric oxide (NO), nitrites, nitrates, carbon monoxide (CO) or carbon dioxide converted from carbon monoxide of INH cleavage are measured. Other embodiments relate to a diagnostic breath test for detecting TB utilizing isotopically labeled urea (preferably, carbon-13 labeled urea), alone or in combination with isotopically labeled isoniazid (preferably, nitrogen-15 labeled isoniazid), wherein M. tuberculosis organism, if present in the patient or subject's lungs (or other tissues), will metabolize the isotopically labeled urea to isotopically labeled carbon dioxide (CO2) such that a determination of the residence of M. tuberculosis, including residence of an isoniazid resistant strain of M. tuberculosis, may be made.

    摘要翻译： 本发明涉及一种用于检测患者或受试者中结核分枝杆菌（结核病或结核病）感染的试验，特别是包括呼吸试验的诊断试验，其中向患者提供小剂量的同位素标记的结核病药物异烟肼（INH ）口服或直接给予患者或受试者的肺。 如果TB存在，TB酶分枝杆菌过氧化物酶KatG氧化INH; 并测定KatG特异性代谢物，特别是同位素标记的一氧化氮（NO），亚硝酸盐，硝酸盐，一氧化碳（CO）或由INH切割的一氧化碳转化的二氧化碳。 其他实施方案涉及用于使用同位素标记的尿素（优选碳-13标记的尿素）单独或与同位素标记的异烟肼（优选氮-15标记的异烟肼）组合来检测结核病的诊断性呼吸试验，其中结核分枝杆菌生物体如果 存在于患者或受试者的肺部（或其他组织）中，将同位素标记的尿素代谢为同位素标记的二氧化碳（CO 2），从而确定结核分枝杆菌的住所，包括结核分枝杆菌的异烟肼抗性菌株的停留 ，可以做。

    Analysis of P. aeruginosa infection in patients
    6.
    发明申请
    Analysis of P. aeruginosa infection in patients 有权
    分析铜绿假单胞菌感染患者

    公开(公告)号：US20080305050A1

    公开(公告)日：2008-12-11

    申请号：US12150199

    申请日：2008-04-25

    申请人： Graham Timmins ,  Vojo P. Deretic

    发明人： Graham Timmins ,  Vojo P. Deretic

    IPC分类号： A61K8/40 ,  G01N33/554 ,  A61K31/17 ,  A61K31/195 ,  A61K33/00

    CPC分类号： C12Q1/04 ,  A61K51/04 ,  A61K51/0406 ,  A61K51/1206 ,  G01N33/497 ,  G01N2333/21

    摘要： The present invention relates to methods for detecting P aeruginosa infection and bacterial burden in the lungs of patients who are at risk for P. aeruginosa infections, especially including patients with Cystic Fibrosis (CF). The present method provides numerous tests (breath, blood, urine) which are readily administered to a patient that will sensitively and specifically detect the presence and extent of lung infection P. aeruginosa (both mucoid and non-mucoid), and allow monitoring of bacterial load as a parameter in monitoring treatment.

    摘要翻译： 本发明涉及用于检测铜绿假单胞菌感染风险的患者肺部铜绿假单胞菌感染和细菌负担的方法，特别是包括囊性纤维化（CF）患者。 本方法提供了许多试验（呼吸，血液，尿液），其易于对患者施用，其将敏感且特异性地检测肺部感染铜绿假单胞菌（粘液样和非粘液样）的存在和程度，并允许监测细菌 负载作为监测治疗的参数。

    TREATMENT OF AUTOPHAGY-RELATED DISORDERS
    8.
    发明申请
    TREATMENT OF AUTOPHAGY-RELATED DISORDERS 审中-公开
    治疗自身免疫性疾病

    公开(公告)号：US20160136123A1

    公开(公告)日：2016-05-19

    申请号：US14898062

    申请日：2014-05-29

    申请人： Vojo P. DERETIC ,  Michale MANDELL ,  STC.UNM

    发明人： Vojo P. Deretic ,  Michael Mandell

    IPC分类号： A61K31/201 ,  C12Q1/61 ,  C12Q1/44 ,  A61K45/06 ,  A61K38/53

    CPC分类号： A61K31/201 ,  A61K38/53 ,  A61K45/06 ,  C12N9/93 ,  C12Q1/44 ,  C12Q1/61 ,  C12Y603/02 ,  G01N2333/92 ,  G01N2405/00 ,  G01N2405/02 ,  G01N2500/20 ,  G01N2800/7028

    摘要： The present invention relates to the use of neutral lipids, including triglycerides, diglycerides and monoglycerides which may be used to increase neutral lipids (lipid stores and/or lipid droplets) and neutral lipid stores in order to regulate (in particular, induce) autophagy and treat and/or prevent autophagy related disease states and/or conditions. In one embodiment, the invention relates to the use of neutral lipids and/or TRIM proteins which may be used to regulate (in particular, induce) autophagy, target autophagic substrates and treat and/or prevent autophagic disease states and/or conditions.

    摘要翻译： 本发明涉及使用中性脂质，包括甘油三酸酯，甘油二酯和甘油单酯，其可用于增加中性脂质（脂质储存和/或脂质液滴）和中性脂质储存物，以调节（特别是诱导）自噬和 治疗和/或预防自噬相关疾病状态和/或病症。 在一个实施方案中，本发明涉及可用于调节（特别是诱导）自噬，靶自噬底物并治疗和/或预防自噬性疾病状态和/或病症的中性脂质和/或TRIM蛋白的用途。